Age: 58.0
Sex: F
Vaccine: COVID19
Symptoms: Influenza
Clinical narrative: INFLUENZA A; This spontaneous case was reported by a consumer and describes the occurrence of INFLUENZA (INFLUENZA A) in a 64-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 prophylaxis.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) for Rheumatoid arthritis.    The patient's past medical history included Cervical cancer in 1985, Hysterectomy in 1985, Tonsillectomy in 2006, Supporting machine, Vaginal mesh removal surgery on 03-Nov-2010, Discectomy on 04-Oct-2012, Surgery and Surgery. Previously administered products included for Drug use for unknown indication: MURINE and PREDNISONE. Past adverse reactions to the above products included Drug allergy with MURINE and PREDNISONE. Concurrent medical conditions included Rheumatoid arthritis since 05-Jan-2012, Degenerative disc disease since 18-Sep-2020, Sleep apnea since May 2013, Abstains from alcohol, Tobacco user, Dry eye syndrome, Fibromyalgia, Osteoarthritis, Plantar fasciitis, Brain tumor, Intervertebral disc herniation, Penicillin allergy and Overactive bladder. Concomitant products included GABAPENTIN, MILNACIPRAN HYDROCHLORIDE (SAVELLA), METHYLPREDNISOLONE, FENOFIBRATE, OMEPRAZOLE, METHIMAZOLE, SALBUTAMOL SULFATE (VENTOLIN HFA), METOCLOPRAMIDE, DEXAMETHASONE, METOPROLOL SUCCINATE, FOLIC ACID, FISH OIL, CALCIUM CARBONATE, COLECALCIFEROL (CALCIUM CARBONATE WITH D3), PARACETAMOL (TYLENOL) and AIRBORNE for an unknown indication.   On 18-Oct-2016, the patient ADALIMUMAB (HUMIRA) (Subcutaneous) dosage was changed to at an unspecified dose. On 05-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 02-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient started ADALIMUMAB (HUMIRA) (Subcutaneous) at an unspecified dose. On an unknown date, ADALIMUMAB (HUMIRA) (Subcutaneous) dosage was changed to at an unspecified dose. In December 2021, the patient experienced INFLUENZA (INFLUENZA A). At the time of the report, INFLUENZA (INFLUENZA A) outcome was unknown.            In Feb-2022 patient started mild hyperthyroidism. On 17-Feb-2022 patient was detected with small cell lung cancer. In Jun-2022 patient started hypertension.  In Dec-2021, patient was diagnosed with influenza A. Treatment detail was not reported. On an unknown date, patient was diagnosed with brain and lung cancer. Patient experienced COVID vaccine related issues flu like symptoms and got very sick following the booster dose. On 19-Jan-2022, patient experienced mild hyperthyroidism and it was low, states its level was 0.14. In 1980, Colonoscopy: Results not provided. On 03-Nov-2011, Bronchoscopy: Results not provided. On an unknown date, Biopsy breast: Results not provided. On an unknown date, Cystometrogram: Results not provided On 10-Feb-2022, Ultrasound of left lung was performed: results not provided.  It was unknown if patient was enrolled in a COVID-19 Vaccine Trial.  This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in.   This case was linked to MOD-2022-623773.   Most recent FOLLOW-UP information incorporated above includes: On 18-Jul-2022: Significant follow up received. Dose details of non-company suspect drug added. On 12-Aug-2022: Significant follow up received. Medical history, concurrent condition and concomitant medications were added. I-narrative updated.